Relmada Therapeutics (RLMD) Osake Kurssi
Relmada Therapeutics Kurssi
Relmada Therapeuticsn liikevaihto on supistunut 28,4 % vuodessa viimeisten 2 vuoden aikana 5 129,00 USD:een. Relmada Therapeuticsn nettomarginaali −877,7 % on laskenut verrattuna −100,0 %:iin muutama vuosi sitten. Relmada Therapeuticsn 12 kuukauden konsensustavoitehinta on 11,00 USD, noin yli kurssia 218,4 %. 11 analyytikosta 10 suosittaa ostoa — kokonaiskonsensus on Osta.
Relmada Therapeutics osakekurssi
Relmada Therapeutics liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Relmada Therapeutics -osakkeesta
Relmada Therapeutics Inc is a pharmaceutical company that focuses on developing and commercializing innovative therapies for various medical conditions. Their business model revolves around researching and developing novel drug candidates, acquiring intellectual property rights, conducting clinical trials, and seeking regulatory approvals for their innovative products. By leveraging their expertise in drug development, Relmada aims to address unmet medical needs and improve patients' quality of life. Through collaborations and strategic partnerships, the company strives to bring their innovative therapies to market and generate value for their stakeholders.
Relmada Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Relmada Therapeutics Inc in the market include companies such as Johnson & Johnson, Pfizer Inc, Novartis AG, and Eli Lilly and Company.
Relmada Therapeutics Inc is a pharmaceutical company specializing in the development and commercialization of novel therapies for various diseases. Founded in 2012, Relmada focuses on innovative solutions to address unmet medical needs and improve patients' lives. The company's research and development efforts primarily concentrate on central nervous system (CNS) disorders, including chronic pain, addiction, and rare diseases. Relmada Therapeutics Inc has successfully advanced several promising drug candidates through preclinical and clinical trials, demonstrating its commitment to delivering effective and safe treatments. With its dedication to scientific advancements, Relmada Therapeutics Inc is poised to make a significant impact in the evolving healthcare industry.
Relmada Therapeutics Inc has achieved several significant milestones. The company successfully completed Phase 2 trials for its lead product, d-Methadone, for the treatment of neuropathic pain. In addition, Relmada Therapeutics received Fast Track designation from the U.S. Food and Drug Administration (FDA) for d-Methadone, which expedites the development and review process. The company also completed a successful IPO, raising $65 million in gross proceeds. Relmada Therapeutics continues to advance its pipeline, focusing on innovative therapies for central nervous system (CNS) disorders. With its groundbreaking achievements, Relmada Therapeutics Inc has positioned itself as a key player in the pharmaceutical industry.
Relmada Therapeutics Inc primarily operates in the United States.
Relmada Therapeutics Inc represents values of innovation, commitment to patient wellbeing, and scientific excellence. The company is dedicated to developing novel therapies to address unmet medical needs. Relmada focuses on advancing research and developing cutting-edge treatments to improve patients' quality of life. Their corporate philosophy revolves around collaboration, ethical practices, and a patient-centric approach. Relmada Therapeutics Inc believes in fostering partnerships and leveraging scientific expertise to create transformative healthcare solutions. Through their dedication to innovation and commitment to advancing medical science, Relmada aims to make a meaningful impact in improving patient outcomes and addressing global healthcare challenges.
Analyytikot asettavat tällä hetkellä Relmada Therapeutics-osakkeelle keskimääräisen tavoitehinnan 11,00 USD (mediaani: 11,00 USD), mikä merkitsee +218,4 % viimeisimpään hintaan verrattuna. Konsensus perustuu 11 analyytikkoarvioon.
11 analyytikkoa arvioi tällä hetkellä Relmada Therapeutics-osaketta: 10 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Relmada Therapeutics-yhtiöltä 10,00 M USD liikevaihtoa ja −0,28 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Relmada Therapeutics-osake noteerataan hintaan 3,08 EUR (3,45 USD).
Relmada Therapeutics-osake (RLMD) on listattuna 3 pörssissä, muun muassa: NASDAQ (RLMD), Frankfurt (4E2.F), München (4E2.MU).
Relmada Therapeutics Inc. is a biopharmaceutical company specializing in the development of novel therapeutics for central nervous system (CNS) disorders. The company is headquartered in New York City and offers a wide range of products and services tailored to the needs of patients and medical professionals. Relmada Therapeutics' business model is based on identifying, developing, and marketing innovative therapeutics for brain disorders and other psychiatric illnesses. The company holds a number of patents for developing biological therapeutics targeting various molecules within the human body. It has established an extensive network of partnerships with leading scientific and medical institutions to conduct a variety of clinical studies that help demonstrate the efficacy and safety of its products. Relmada Therapeutics' portfolio includes a range of novel therapeutics that can be used to treat a variety of psychiatric disorders. The company specializes in the development of preparations for the treatment of pain, depression, and addiction. Its flagship product is REL-1017, which targets the glutamatergic receptor and is currently in phase 3 clinical trials for the treatment of depression. In addition to its product pipeline, Relmada Therapeutics also offers a comprehensive range of services for medical professionals and patients. The company has a team of experienced clinical experts who assist customers in developing individualized treatment plans tailored to the specific needs of each patient. Relmada Therapeutics has also built a wide range of partnerships and alliances with key players in the pharmaceutical industry and healthcare. These partnerships enable the company to further expand its product development activities and improve the global marketing of its therapeutics. Overall, Relmada Therapeutics is an innovative biopharmaceutical company focused on improving the treatment of psychiatric disorders. Its comprehensive portfolio of products and services for medical professionals and patients, its experienced clinical experts, and its strong partnerships with other key players in the industry make it a significant player in the global market for psychiatric medications.
odotettu liikevaihto Relmada Therapeutics on 10,00 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Relmada Therapeutics on −18,78 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Relmada Therapeutics:n hinta-voitto-suhde (P/E) on tällä hetkellä −12,56. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Relmada Therapeutics-osakkeen arvostusta.
Relmada Therapeutics:n hinta-myynti-suhde (P/S) on tällä hetkellä 23,58. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Relmada Therapeutics-osakkeen arvostuskennuslukuna.
Relmada Therapeutics:n Eulpool-laatuscore on 2/10.
Relmada Therapeutics:n ISIN on US75955J4022. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Relmada Therapeutics:n WKN on A2PSZF. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Relmada Therapeutics:n ticker on RLMD. Tämä pörssinoteeraus käytetään Relmada Therapeutics-osakkeiden kauppaan pörssissä.
Relmada Therapeutics osake
Relmada Therapeutics vertaisryhmä
Relmada Therapeutics Ticker
Relmada Therapeutics FIGI
Kaikki tunnusluvut ja syvällinen analyysi Relmada Therapeutics:sta
Meidän osakeanalyysimme Relmada Therapeutics-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Relmada Therapeutics:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: